Personal information

Other IDs

Scopus Author ID: 57202733493
SciProfiles: 905478

Countries

Italy

Activities

Collapse all

Employment (3)

University of Modena and Reggio Emilia: Modena, IT

2021-11-01 to present | PhD student in Clinical and Experimental Medicine
Employment
Source: Self-asserted source
Giulia Rovesti

University Hospital of Modena: Modena, IT

2021-11-01 to present | Medical Oncologist
Employment
Source: Self-asserted source
Giulia Rovesti

Università degli Studi di Modena e Reggio Emilia Facoltà di Medicina e Chirurgia: Modena, Emilia-Romagna, IT

2016-11-01 to 2021-11-01 | Trainee in Medical Oncology
Employment
Source: Self-asserted source
Giulia Rovesti

Works (15)

Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma

npj Precision Oncology
2024-02-01 | Journal article
DOI: 10.1038/s41698-024-00506-z
Contributors: Chiara Chiavelli; Malvina Prapa; Giulia Rovesti; Marco Silingardi; Giovanni Neri; Giuseppe Pugliese; Lucia Trudu; Massimiliano Dall’Ora; Giulia Golinelli; Giulia Grisendi et al.
Source: check_circle
Crossref

Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board

Nutrients
2021-10-07 | Journal article
DOI: 10.3390/nu13103522
Contributors: Giulia Rovesti; Filippo Valoriani; Margherita Rimini; Camilla Bardasi; Roberto Ballarin; Fabrizio Di Benedetto; Renata Menozzi; Massimo Dominici; Andrea Spallanzani
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy

Cancers
2021-08-27 | Journal article
DOI: 10.3390/cancers13174334
Contributors: Panagiota Maravelia; Daniela Nascimento Silva; Giulia Rovesti; Michael Chrobok; Per Stål; Yong-Chen Lu; Anna Pasetto
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Recent Research on Gastrointestinal Carcinoma

Cancers
2021-01-18 | Journal article
DOI: 10.3390/cancers13020333
Contributors: Giulia Rovesti; Giorgia Marisi; Andrea Casadei-Gardini
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review

Pharmaceuticals
2021-01-08 | Journal article
DOI: 10.3390/ph14010043
Contributors: Francesca Matilde Schipilliti; Ingrid Garajová; Giulia Rovesti; Rita Balsano; Federico Piacentini; Massimo Dominici; Fabio Gelsomino
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives

Cancers
2020-11-12 | Journal article
DOI: 10.3390/cancers12113346
Contributors: Eleonora Molinaro; Kalliopi Andrikou; Andrea Casadei-Gardini; Giulia Rovesti
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial

Therapeutic Advances in Medical Oncology
2020-01 | Journal article
DOI: 10.1177/1758835920958363
Contributors: Andrea Casadei Gardini; Emanuela Scarpi; Martina Valgiusti; Manlio Monti; Silvia Ruscelli; Laura Matteucci; Giulia Bartolini; Bernadette Vertogen; Flavia Pagan; Giulia Rovesti et al.
Source: check_circle
Crossref

1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages

Cancers
2020-01-18 | Journal article
DOI: 10.3390/cancers12010241
Contributors: Andrea Casadei-Gardini; Laura Del Coco; Giorgia Marisi; Fabio Conti; Giulia Rovesti; Paola Ulivi; Matteo Canale; Giovanni Luca Frassineti; Francesco Giuseppe Foschi; Serena Longo et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy

Cancer Gene Therapy
2019 | Journal article
DOI: 10.1038/s41417-018-0034-1
EID:

2-s2.0-85049130616
Contributors: Rossignoli, F.; Grisendi, G.; Spano, C.; Golinelli, G.; Recchia, A.; Rovesti, G.; Orsi, G.; Veronesi, E.; Horwitz, E.M.; Dominici, M.
Source: Self-asserted source
Giulia Rovesti via Scopus - Elsevier

MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma

Theranostics
2019 | Journal article
DOI: 10.7150/thno.27576
EID:

2-s2.0-85059508592
Contributors: Rossignoli, F.; Spano, C.; Grisendi, G.; Foppiani, E.M.; Golinelli, G.; Mastrolia, I.; Bestagno, M.; Candini, O.; Petrachi, T.; Recchia, A. et al.
Source: Self-asserted source
Giulia Rovesti via Scopus - Elsevier

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

Scientific Reports
2019 | Journal article
DOI: 10.1038/s41598-018-37433-6
EID:

2-s2.0-85061240519
Contributors: Spano, C.; Grisendi, G.; Golinelli, G.; Rossignoli, F.; Prapa, M.; Bestagno, M.; Candini, O.; Petrachi, T.; Recchia, A.; Miselli, F. et al.
Source: Self-asserted source
Giulia Rovesti via Scopus - Elsevier

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

Journal of Hepatology
2019-12 | Journal article
DOI: 10.1016/j.jhep.2019.08.015
Contributors: Francesco Tovoli; Luca Ielasi; Andrea Casadei-Gardini; Alessandro Granito; Francesco Giuseppe Foschi; Giulia Rovesti; Giulia Negrini; Giulia Orsi; Matteo Renzulli; Fabio Piscaglia
Source: check_circle
Crossref

Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience

Gastrointestinal Tumors
2019-09-12 | Journal article
DOI: 10.1159/000502714
Part of ISSN: 2296-3774
Part of ISSN: 2296-3766
Source: Self-asserted source
Giulia Rovesti

Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort

Gastrointestinal Tumors
2019-08-20 | Journal article
DOI: 10.1159/000501593
Part of ISSN: 2296-3774
Part of ISSN: 2296-3766
Source: Self-asserted source
Giulia Rovesti

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

Cancers
2019-07-20 | Journal article
DOI: 10.3390/cancers11071023
Part of ISSN: 2072-6694
Source: Self-asserted source
Giulia Rovesti
How many people are using ORCID?